Biotron Limited (ASX: BIT)
Health Care · Biotechnology · AU
AU$0.00
-20.00% today · -42.9% 1Y
Biotron Limited (ASX: BIT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.87M and employs 4 people.
Over the last twelve months the share price has lost 42.9%, trading between 0.00 and 0.01.
Tweenvest scores Biotron Limited across four factors: quality 36/100, value 42/100. Its strongest factor is value.
BIT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.87M
- Revenue (TTM)
- $363.80K
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- -0.64
- 52-week high
- AU$0.01
- 52-week low
- AU$0.00
- Avg volume (3M)
- —
- Shares outstanding
- 2.79B
- Employees
- 4
- Next earnings
- —
About Biotron Limited
Biotron Limited is an Australian biotechnology firm dedicated to the creation and market introduction of small molecule therapies designed to combat a range of viral illnesses. Its flagship antiviral compound, BIT225, is currently undergoing Phase II clinical evaluations for addressing infections caused by SARS-CoV-2, HIV-1, and the hepatitis C virus. Established in 1999, the company operates from its main office in Sydney, Australia.
- ISIN
- AU000000BIT4
- Founded
- 1999
- Listed since
- Jan 23, 2001
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Telo Genomics Corp.TSXV: TELO | $4.23M | CA$0.05 | -16.67% |
| Predilife S.A.ENXTPA: ALPRE | $4.02M | €0.91 | -0.44% |
| Tecnovatica S.A.WSE: TEC | $4.00M | zł0.44 | -0.68% |
| Calidi Biotherapeutics, Inc.NYSEAM: CLDI | $3.99M | $1.04 | -3.70% |
| Genetic Analysis ASXSAT: GEAN | $3.82M | Nkr0.48 | -9.43% |
| Tissue Repair LtdASX: TRP | $3.78M | AU$0.09 | +9.76% |
| Eocene Ltd.NasdaqCM: EOCN | $3.76M | $3.62 | +0.28% |
| Bharat Immunologicals & Biologicals Corporation LimitedBSE: 524663 | $3.67M | Rs8.18 | -37.13% |
Figures last refreshed Oct 4, 2026.